Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


Tirabrutinib in the glossary for Waldenström's macroglobulinemia

A second generation small molecule inhibitor of Bruton's tyrosine kinase

Tirabrutinib is a selective, irreversible, second-generation, small-molecule BTK inhibitor. Oral tirabrutinib is approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. Clinical development is underway in the USA, Europe and Japan for chronic lymphocytic leukaemia, B cell lymphoma, Sjogren's syndrome, pemphigus and rheumatoid arthritis. Tirabrutinib is not licensed for use in the EU.

Glossary overview